Clinical Utility of ESWT in Restoring Hand Function of Patients With Nerve Injury and Hypertrophic Scars Due to Burns
Launched by HANGANG SACRED HEART HOSPITAL · May 27, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the use of Extracorporeal Shock Wave Therapy (ESWT) to help improve hand function in patients who have experienced nerve injuries and thick scars from burns. After a burn, many people can have difficulty moving their hands due to joint stiffness and nerve damage. The researchers want to see if ESWT can help reduce pain, improve hand movement, and make the scars less noticeable. Participants will receive 12 weekly treatments of ESWT, while some may receive a placebo treatment that does not have any real effect, to compare the results.
To join the study, participants must be at least 18 years old and have had a deep or full-thickness burn on their dominant hand that was treated with a skin graft. They should also have confirmed nerve injury in the hand within the last six months. However, people with certain hand injuries, infections, or other specific health issues may not be eligible. Throughout the trial, participants will undergo various tests to measure pain, hand function, grip strength, and the condition of their scars before and after the treatment period. This study aims to provide valuable insights into how ESWT can help improve recovery for patients with hand injuries due to burns.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ≥ 18 years old
- • had sustained a deep partial-thickness (second-degree) or a full-thickness (third-degree) burn in the right dominant hand, which had been treated with a split-thickness skin graft (STSG) after the thermal injury
- • nerve injury to the hand was confirmed by electromyography
- • \< 6 months prior to the enrollment
- Exclusion Criteria:
- • musculoskeletal diseases (fracture, amputation, rheumatoid arthritis, and degenerative joint diseases) of the hands
- • acute infection
- • malignant tumors
- • coagulopathy
- • pregnancy
- • potential for additional skin damage if exposed to ESWT and conventional occupational therapy.
About Hangang Sacred Heart Hospital
Hangang Sacred Heart Hospital is a prominent healthcare institution dedicated to advancing medical research and patient care. With a strong commitment to innovation and excellence, the hospital serves as a key clinical trial sponsor, facilitating cutting-edge studies that aim to enhance treatment options and improve health outcomes. Equipped with state-of-the-art facilities and a team of experienced researchers and healthcare professionals, Hangang Sacred Heart Hospital prioritizes ethical standards and patient safety in all its clinical trials, fostering collaboration with academic institutions and industry partners to drive meaningful advancements in medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Trial Officials
SO YOUNG JOO
Principal Investigator
handgang sacred heart hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported